LAST WEEK TODAY!

A summary of what was published on ProstateWarriors.com during the past week

Hello fellow warriors! This week I selected the studies I’ll be following during the ASCO 2026 annual meeting, which will take place at the end of the month. There are some very interesting things! But for now, let’s start with this week’s newsletter.
Stay strong and fight on!

As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE.
​​

Clinical Research

• Phase 2 Trial: HS-20093 and the ARTEMIS-003 Study​
  The HS-20093 (risvutatug rezetecan) antibody-drug conjugate (ADC) has received Breakthrough Therapy designation in China for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This therapy targets the B7-H3 protein to deliver a cytotoxic payload directly to tumor cells. Results from the ARTEMIS-003 trial presented in 2026 showed a confirmed objective response rate of 38.9% in taxane-pretreated patients and 50.0% in taxane-naive patients, with a safety profile described as generally manageable.​
  ​
• Phase 2 Trial: TLX597-Tx and the OPTIMAL-PSMA Study​
  New data from the randomized OPTIMAL-PSMA trial indicates that TLX597-Tx is a promising next-generation radioligand therapy for mCRPC. This treatment is designed to deliver radiation precisely to prostate cancer cells while maintaining a favorable dosimetry profile, showing relatively low radiation exposure to the kidneys and salivary glands. These findings suggest that the drug can support intensified dosing schedules, potentially allowing clinicians to push treatment harder against the tumor without increasing toxicity to critical normal tissues.​
  ​
• Phase 1 Trial: BPX-601 Controlled CAR T-Cell Therapy​
  A Phase 1 clinical trial has launched to evaluate BPX-601, an innovative CAR T-cell therapy featuring a built-in “go-switch” safety mechanism. This mechanism allows doctors to turn the engineered immune cells on or off using a separate drug, a control intended to prevent the dangerous immune over-activity often associated with CAR-T technology. While a previous iteration of the therapy achieved a ≥50% reduction in PSA for 56% of patients, it also caused serious complications at higher doses; the current trial aims to establish the safest and most effective dose for men with advanced disease.​
  ​
• B7-H3 Emerges as a Universal Prostate Cancer Target​
  Analysis of the JHU-PANORAMA single-cell atlas has identified B7-H3 (CD276) as a standout therapeutic target across all stages of prostate cancer, including hormone-sensitive, castration-resistant, and neuroendocrine subtypes. Unlike many other targets that are androgen receptor (AR)-dependent or highly variable, B7-H3 expression is remarkably consistent and uniform. Research indicates that androgen deprivation therapy (ADT) actually increases the accessibility of B7-H3, suggesting that combining B7-H3 inhibition with standard hormone treatments could deliver synergistic tumor suppression.​

​

Preclinical Research & Reviews

• Drugging the “Undruggable” Androgen Receptor N-Terminal Domain​
  Researchers from the University of British Columbia have successfully designed compounds that target the androgen receptor’s N-terminal domain (NTD/TAD), a region previously considered “undruggable” due to its flexible, disordered shape. These new molecules bind up to a million times tighter than previous attempts, freezing the domain in a non-functional state and blocking the activation of cancer-driving genes. In laboratory and animal models, these compounds outperformed standard therapies and shut down receptor activity even in resistant tumors where traditional drugs like enzalutamide fail.​
  ​
• GX-BP1: A BioPROTAC Targeting SOX2 Resistance​
  The novel bioPROTAC GX-BP1 selectively targets the SOX2 protein for elimination via the ubiquitin-proteasome system to overcome therapy resistance in mCRPC. SOX2 is a key transcription factor that promotes cancer stem cell maintenance and the development of aggressive neuroendocrine phenotypes. Preclinical studies demonstrated that GX-BP1 monotherapy achieved 70% tumor growth inhibition, and when paired with other agents, it reached up to 96% inhibition, offering a way to restore sensitivity to standard treatments and prolong survival.​

​

And…that’s all folks! For today at least!
Please let me know if there is anything I can improve in my newsletters, and let me know if you have enjoyed the podcast.

If this newsletter was delivered to your SPAM folder, make sure to let your email system know that it is not spam.
​
​
Have a great weekend!

Max